Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The study was performed to assess: 1) clinical activity of Imatinib in patients with HES, CEL
and CIH; 2) correlation between Imatinib activity and specific disease subtype; 3) long-term
outcome of HES, CEL and CIH patients treated with Imatinib; 4) safety and tolerability of
Imatinib administration.